Scilex Holding Company (NASDAQ:SCLX) Financings

Scilex Holding Company

Financings

RaiseDate
Strategic investment of newly issued shares of common stock
Announced: US$100M · US$10 a share
Buyers: iHolding Group LLP ($100,000,000 of newly issued shares of Semnur common stock)
Use of proceeds: Pipeline advancement incl. Phase 3 SEMDEXA (SP-102), commercialization, acquisitions and partnerships, working capital, IP, general corporate purposes
Jul 7, 2026
Strategic investment of common stock
Announced: US$100M · US$15 a share
Buyers: iHolding Group LLP ($100,000,000 of newly issued shares of common stock at $15.00 per share, approximately 6,666,667 shares)
Use of proceeds: Strategic growth, healthcare and medtech initiatives, product development, acquisitions and partnerships, working capital, IP and general corporate purposes
Jul 6, 2026
Warrant exercise of shares of common stock on exercise of existing warrants
Closed: US$20.3M raised · US$22.51 a share · Warrants at US$29 for 60 months · Rodman & Renshaw LLC +1
Dealers: Rodman & Renshaw LLC (co-lead), StockBlock Securities LLC (co-lead)
Use of proceeds: Working capital and general corporate purposes
Nov 25, 2025
Registered direct offering of common stock, pre-funded warrants and accompanying common warrants
Announced: about US$17M · US$0.59 a share · ½ warrant at US$0.649
Use of proceeds: Working capital and general corporate purposes, including commercialization, R&D, clinical trials, acquisitions and debt repayment
Dec 12, 2024
Warrant exercise of outstanding warrants issued in March 2024
Announced: about US$1M · US$0.59 a share
Dec 12, 2024

Read by 6ix AI from the company's releases